Kezar Life Sciences (NASDAQ:KZR) Receives Neutral Rating from HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a report released on Monday, Benzinga reports.

Kezar Life Sciences Price Performance

NASDAQ:KZR opened at $0.87 on Monday. Kezar Life Sciences has a 1-year low of $0.52 and a 1-year high of $1.14. The company has a 50-day moving average of $0.64 and a 200 day moving average of $0.69. The firm has a market cap of $63.34 million, a PE ratio of -0.62 and a beta of 0.21. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, research analysts anticipate that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Kezar Life Sciences in the 2nd quarter worth approximately $63,000. Stonepine Capital Management LLC acquired a new stake in shares of Kezar Life Sciences during the 2nd quarter worth approximately $630,000. Mackenzie Financial Corp acquired a new stake in shares of Kezar Life Sciences during the 2nd quarter worth approximately $35,000. Acadian Asset Management LLC grew its stake in shares of Kezar Life Sciences by 3.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after purchasing an additional 64,356 shares during the period. Finally, Acuitas Investments LLC grew its stake in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after purchasing an additional 295,956 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.